Biogen Pays $3.25B For Stake In Elan's MS Drug
Irish drugmaker Elan Corp. PLC is selling its stake in blockbuster multiple sclerosis medicine Tysabri for $3.25 billion plus royalties to longtime partner Biogen Idec Inc., Elan said Wednesday, delivering a...To view the full article, register now.
Already a subscriber? Click here to view full article